Aspirin Drug Resistance in Coronary Heart Disease Patients: A Literature Review
Article Sidebar
Main Article Content
Page: 1113-1122
Abstract
In Indonesia, coronary heart disease is the largest contributor to mortality with a prevalence related to cardiovascular disease. Using drugs from a combination of fibrinolytics, anticoagulants, and antiplatelets can overcome acute coronary heart disease. The most commonly used therapy is the antiplatelet class in the form of aspirin as a treatment for the management of cardiovascular disease and its prevention. However, several studies have stated that aspirin is a conventional antiplatelet which sometimes has the potential to cause failure and is ineffective for the treatment of coronary heart disease, so that it can be said to be aspirin resistance. Article writing method review This study uses scientific literature. The steps taken begin with collecting various journal references through the database PubMed Identifier (PMID), google schoolar, and science direct within the last 10 years (2013-2023). The keyword in the literature search is aspirin resistance, aspirin resistance coronary disease, and aspirin coronary heart diseases. Based on the results of reviews that have been reviewed, it shows that there are resistance mechanisms and factors that influence aspirin resistance in coronary heart disease patients.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Chang, R., Wu, J., Han, C., Liu, Y., Liu, X., Ye, Y., & Zhou, W. (2021). Ajtr0013-9024.Pdf. 13(8), 9024–9031.
Dehne, S., Heck, C., Sander, J., Meisenbacher, K., Arens, C., Niklas, C., … Larmann, J. (2022). Editor’s Choice – Association Between Peri-OPerative Aspirin ResisTance and CardioVascular Outcome (POPART-CVO): a Prospective Non-Interventional Cohort Study. European Journal of Vascular and Endovascular Surgery, 64(4), 407–415. https://doi.org/10.1016/j.ejvs.2022.07.050
Han, Y. (2016). Aspirin resistance in coronary heart disease: Current understandings and strategies. Journal of Translational Internal Medicine, 4(1), 7–10. https://doi.org/10.1515/jtim-2016-0002
Li, J., Song, M., Jian, Z., Guo, W., Chen, G., Jiang, G., … Huang, L. (2014). Laboratory aspirin resistance and the risk of major adverse cardiovascular events in patients with coronary heart disease on confirmed aspirin adherence. Journal of Atherosclerosis and Thrombosis, 21(3), 239–247. https://doi.org/10.5551/jat.19521
Mudassar Noor , Usman Nawaz , Imran Fazal , Akbar Waheed (2018). Aspirin Resistance : an Emerging Threat To Cardiovascular. 51(02), 119–123.
Salah, A., El-Desuky, M., Rizk, A., & El-Hadidy, A. (2015). Aspirin resistance: Prevalence and clinical outcome in Egypt. The Egyptian Journal of Critical Care Medicine, 3(1), 23–27. https://doi.org/10.1016/j.ejccm.2014.12.001
Wang, X., Han, L., & Yang, J. (2022). Evaluation of efficacy and safety of aspirin combination treatment in treating patients with coronary heart disease. Medicine, 101(7), e28848. https://doi.org/10.1097/md.0000000000028848
Yunita, E. P., Zulkarnain, B. S., & Aminuddin, M. (2015). Aspirin Resistance in Coronary Artery Disease with Hypertensive Patients. Indonesian Journal of Clinical Pharmacy, 4(1), 28–38. https://doi.org/10.15416/ijcp.2015.4.1.28
Zeng, W., Chu, T. T. W., Chow, E. Y. K., Hu, M., Fok, B. S. P., Chan, J. C. N., … Tomlinson, B. (2022). Factors Associated with Aspirin Resistance in Hong Kong Chinese Patients with Stable Coronary Heart Disease Using the Multiplate® Analyzer and Serum